Association of incretin receptors genetic polymorphisms with type 2 diabetes mellitus in Egyptian patients

Shalaby, Sally M.; Zidan, Haidy E.; Shokry, Amira; Saeed, Jehan; El-Sokkary, Rehab H.

doi:10.1002/jgm.2973

Cited by 10 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Associations with T2DM risk were investigated in a study that included 150 T2DM patients and 150 healthy controls from Egypt. This study found no association of GLP1R rs367543060 polymorphism with T2DM, although they have observed significantly lower GLP-1 levels in diabetic patients than controls [ 62 ].…”

Section: Genetic Variability Of the Incretin Systemmentioning

confidence: 85%

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Klen

Dolžan

2022

IJMS

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow gastric emptying time, and increase insulin action on peripheral tissue. They are effective in the management of type 2 diabetes mellitus and have a favorable effect on weight loss. Their cardiovascular and renal safety has been extensively investigated and confirmed in many clinical trials. Recently, evidence has shown that in addition to the existing approaches for the treatment of obesity, semaglutide in higher doses promotes weight loss and can be used as a drug to treat obesity. However, some T2DM and obese patients do not achieve a desired therapeutic effect of GLP-1 receptor agonists. This could be due to the multifactorial etiologies of T2DM and obesity, but genetic variability in the GLP-1 receptor or signaling pathways also needs to be considered in non-responders to GLP-1 receptor agonists. This review focuses on the pharmacological, clinical, and genetic factors that may influence the response to GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus and obesity.

show abstract

Section: Genetic Variability Of the Incretin Systemmentioning

confidence: 85%

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Klen

Dolžan

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Shalaby group [24] studied rs1800437 polymorphism in Egyptian T2DM patients. Their findings indicated that the distribution of C haplotype is statistically higher in patients than controls.…”

Section: Discussionmentioning

confidence: 99%

Association of gastric inhibitory polypeptide receptor (GIPR) gene polymorphism with type 2 diabetes mellitus in iranian patients

et al. 2023

View full text Add to dashboard Cite

Introduction Gastric inhibitory polypeptide receptor (GIPR) encodes a G-protein coupled receptor for gastric inhibitory polypeptide (GIP), which was demonstrated to stimulate insulin secretion. Relation of GIPR gene variation to impaired insulin response has been suggested in previous studies. However, little information is available regarding GIPR polymorphisms and type 2 diabetes mellitus (T2DM). Hence, the aim of the study was to investigate single nucleotide polymorphisms (SNPs) in the promoter and coding regions of GIPR in Iranian T2DM patients. Materials and methods Two hundred subjects including 100 healthy and 100 T2DM patients were recruited in the study. Genotypes and allele frequency of rs34125392, rs4380143 and rs1800437 in the promoter, 5ʹ UTR and coding region of GIPR were investigated by RFLP-PCR and Nested-PCR. Results Our finding indicated that rs34125392 genotype distribution was statistically different between T2DM and healthy groups (P = 0.043). In addition, distribution of T/- + -/- versus TT was significantly different between the both groups (P = 0.021). Moreover, rs34125392 T/- genotype increased the risk of T2DM (OR = 2.68, 95%CI = 1.203–5.653, P = 0.015). However, allele frequency and genotype distributions of rs4380143 and rs1800437 were not statistically different between the groups (P > 0.05). Multivariate analysis showed that the tested polymorphisms had no effect on biochemical variables. Conclusion We concluded that GIPR gene polymorphism is associated with T2DM. In addition; rs34125392 heterozygote genotype may increase the risk of T2DM. More studies with large sample size in other populations are recommended to show the ethnical relation of these polymorphisms to T2DM.

show abstract

“…This variant was also independently associated with protection against coronary heart disease [61]. Additionally, GLP-1R genetic polymorphisms have been associated with increased T2DM and/or coronary heart disease risk in East Asian [66], Egyptian [67], Japanese [63,68] and Chinese populations [69].…”

Section: Polymorphisms Of the Glp1r Genementioning

confidence: 96%

New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling

Tomás

Jones

Leech

2020

Journal of Molecular Biology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Association of incretin receptors genetic polymorphisms with type 2 diabetes mellitus in Egyptian patients

Cited by 10 publications

References 52 publications

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Association of gastric inhibitory polypeptide receptor (GIPR) gene polymorphism with type 2 diabetes mellitus in iranian patients

New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling

Contact Info

Product

Resources

About